Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 5/20 | 0.40 |
| ▸ | VDR | P11473 | 6/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.38 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | SLC26A4 | O43511 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488725 | 0.92 | ALOX5AP (0.37) | ALOX5APVDRNR1H4PPARGTP53 | |
| SCHEMBL6490177 | 0.91 | BCL2 (0.42) | ALOX5APVDRNR1H4TRPM4TP53 | |
| SCHEMBL6489403 | 0.89 | PIK3C2B (0.40) | ALOX5APTRPM4PPARGALOX5 | |
| SCHEMBL6497504 | 0.88 | ALOX5AP (0.45) | ALOX5APPPARGTP53MAPTMEN1 | |
| SCHEMBL6498329 | 0.85 | MAPT (0.41) | ALOX5APTRPM4PPARGTP53MAPT | |
| SCHEMBL6492244 | 0.82 | PPARG (0.46) | ALOX5APPPARG | |
| SCHEMBL6487283 | 0.81 | PIK3C2B (0.35) | MAPT | |
| SCHEMBL6488053 | 0.81 | BCL2 (0.43) | TRPM4 | |
| SCHEMBL6488086 | 0.81 | ALOX5AP (0.42) | ALOX5APPPARGTP53MAPTMEN1 | |
| SCHEMBL6491428 | 0.80 | BCL2 (0.46) | ALOX5APPPARGTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | ALOX5AP 4663/4885VDR 2245/4885NR1H4 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.